Amgen to Acquire Rodeo Therapeutics for ~$721M

Shots:

• Amgen to acquire all outstanding shares of Rodeo for a $55M upfront along with ~$666M in cash as contingent milestones
• The acquisition will strengthen Amgen’s inflammation portfolio with the addition of Rodeo’s 15-PGDH program
• Rodeo’s 15-PGDH has the potential in its preclinical studies and have clinical potential in multiple indications

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire